leisure time -WSS

leisure time

author：entertainment 2025-10-02 22:40:38 - browse：589

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： What we’ve learned from the Aduhelm mess

WSS

Key House Republican on health care plans exit from Congress

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

A disappointing year of Humira biosimilars

It's time to take a new tack for treating Alzheimer's

Medicare Advantage proposed rates disappoint insurers

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Wikipedia

leisure time

explore

Peter Hotez and the public health issue of online harassment

For Medicare Advantage, Democrats want stronger protections around AI

Virginia high school admissions case could be legal follow

Biden report: The neurospychology of memory and aging

How to save PrEP access — and even expand it

PhRMA lawsuit over Medicare drug price negotiation tossed

Heart attack and stroke risk calculators need revising

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Bright Health sells Medicare Advantage business to Molina

A former Republican legislative candidate has been charged for his role in the US Capitol riot

knowledge

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

KalVista pill reduced swelling 'attacks' caused by genetic disease

PhRMA lawsuit over Medicare drug price negotiation tossed

Suspects arrested after 3 women attacked on Manhattan's West Side: Police

Biden report: The neurospychology of memory and aging

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

explore

Wikipedia

hotspot

focus